Author

Stanislav Gobec

University of LjubljanaORCID 0000-0002-9678-3083Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. MedeniD· 1 shared Adolfo García-Pérez· 1 shared Alfonso Mendoza-LosanaiD· 1 shared Andrej PerdihiD· 1 shared Anja Hafner PišlariD· 1 shared Celine Dalle· 1 shared Chang‐Guo ZhaniD· 1 shared Damijan KneziD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. MedenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tunable nucleofugality in carbamoyl-bearing covalent cholinesterase inhibitors

A. Meden, Damijan Knez, Xi Chen, Linhui Li, Xavier Brazzolotto, Maša Zorman, Anja Hafner Pišlar, Andrej Perdih, Fabrice Modeste, Celine Dalle, Milica Denic, Fabien Chantegreil, José Dias, Janez Ilaš, Janez Košmrlj, , Stanislav Gobec

This study explores carbamoyl warhead reactivity in covalent cholinesterase inhibitors, identifying structure-reactivity relationships and demonstrating a highly selective, irreversible inhibitor.

bioRxiv · Aug 20, 2025 · PreprintPharmacology & Toxicology

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

Lourdes Encinas, Si‐Yang Li, Joaquín Rullás, Rokeya Tasneen, Sandeep K. Tyagi, Heena Soni, Adolfo García-Pérez, Jin Lee, Rubén González del Río, Jaime de Mercado, Verónica Sousa, Izidor Sosič, Stanislav Gobec, Alfonso Mendoza-Losana, Paul J. Converse, , Eric L. Nuermberger

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Antimicrobial Agents and Chemotherapy · Sep 30, 2024Peer-reviewedPharmacology & Toxicology